Protein A Resin Market to cross USD 1,020.7 Million in 2030

Isabella Turner

Public and private organizations are making huge investments in protein-based research and development (R&D). In recent past, the development of monoclonal antibodies and proteins as therapeutic agents was avoided by pharmaceutical firms, on account of their size, poor delivery, low stability, and rate of degradation. However, the companies are focusing on the development of proteins and monoclonal antibodies as therapeutics to address the unmet requirements in several therapeutic areas, including oncology, metabolic diseases, cardiovascular disorders, and infectious diseases. This has increased the usage of proteins that imitate the functions of mediators.

Receive Sample Copy of this Report:

The increasing R&D activities along with surging burden of chronic diseases and booming geriatric population will drive the protein A resin market at 7.0% CAGR during 2020–2030. The market was valued at $486.4 million in 2019, and it is expected to generate $1,020.7 million by 2030. According to the United Nations Population Fund, around 22% of global population will aged 60 years or above by 2050. The elderly more vulnerable to chronic diseases and rising cases of such ailments would boost the demand for new protein-based therapeutic agents for disease management.

Several key players in the protein A resin market have been involved in partnership and collaboration activities with the aim to develop advanced next-generation protein A resins and launch novel products. For example, Bio-Works Technologies AB signed a distribution agreement with Gene Company Ltd., a Hong Kong-based company, in October 2019. According to the terms of this agreement, Gene Company Ltd. would import, store, promote, market, distribute, and sell products manufactured by Bio-Works Technologies AB.

Moreover, other key players including Merck KGaA, Repligen Corporation, Purolite Corporation, Repligen Corporation, Tosoh Corporation, Thermo Fisher Scientific Inc., GE Healthcare, Bio-Works Technologies AB, Kaneka Corporation, Expedeon AG, Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Amikozen Co. Ltd., and Novasep Holding SAS are also focusing on acquiring other companies to gain more customers and expanding their reach. For instance, General Electric Company entered into an agreement with Danaher Corporation, in February 2019, to sell its biopharma business.

Globally, the North American protein A resin market generated the highest revenue in 2019, due to the escalating adoption of protein-based therapeutics for triatic critical medical conditions and soaring number of the Food and Drug Administration (FDA) approvals for biopharmaceuticals in the region. Additionally, strong presence of large-scale drug manufacturers like Bayer AG and Gilead Sciences Inc. and the expansion of biopharma research sector are also supporting market growth. The U.S. is the larger contributor to the regional market, on account of rising incidence of chronic diseases and increasing number of protein-related R&D activities.

Whereas, the Asia-Pacific (APAC) market will register the fastest in the coming years, on account of the growing usage of protein A resins in drug recovery and increasing frequency of life sciences research activities. Moreover, continuous advancements in technologies will also boost the usage of protein A resins in the region. Japan is the leading contributor to the APAC market, as the country hosts some of the pharmaceutical giants like Takeda Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., and Astellas Pharma Inc. and invests heavily in R&D activities to develop advanced drugs.

Thus, the rising number of R&D activities, growing elderly population, and increasing collaborations and partnerships will fuel the utilization for protein A resins in the coming years.

Leave a Comment